Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus
Aim. To investigate the efficacy and safety of glimepiride as initial mono-therapy in type 2 diabetes patients (T2DM). Materials and Methods. This is a multi-center, open-label prospective observational study. 245 treatment-naive T2DM patients, who had not achieved glycemic goals on lifestyle the...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2013-12-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6276 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850141109478490112 |
|---|---|
| author | Alexander Sergeevich Ametov Fatima Totrazovna Abaeva |
| author_facet | Alexander Sergeevich Ametov Fatima Totrazovna Abaeva |
| author_sort | Alexander Sergeevich Ametov |
| collection | DOAJ |
| description | Aim. To investigate the efficacy and safety of glimepiride as initial mono-therapy in type 2 diabetes patients (T2DM). Materials and Methods. This is a multi-center, open-label prospective observational study. 245 treatment-naive T2DM patients, who had not achieved glycemic goals on lifestyle therapy during first 12 weeks after the diagnosis, were enrolled in this study. Anti-diabetes treatment was initiated with glimepiride and continued during the 6-month follow-up period. Prescription of the initial dose (1 mg per day) and further dose adjustments were carried out by the attending physician in accordance with the glimepiride data sheet. Dynamics of HbA1c, fasting plasma glucose (FPG), 2 h postprandial blood glucose (2hPPG), weight and waist circumference, as well as the incidence of hypoglycemia were the evaluated parameters. Results. The baseline HbA1c (mean: 7.9?0.5%; female: 7.8?0.4% ; male: 8.0?0.6%) was significantly reduced at week 12 (mean 7.2?0.6%, p |
| format | Article |
| id | doaj-art-3dd493e044804230a221fbe2dc9499dc |
| institution | OA Journals |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2013-12-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-3dd493e044804230a221fbe2dc9499dc2025-08-20T02:29:34ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782013-12-011649510010.14341/DM2013495-1006223Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitusAlexander Sergeevich Ametov0Fatima Totrazovna Abaeva1Russian Medical Academy of Postgraduate Education, MoscowRussian Medical Academy of Postgraduate Education, MoscowAim. To investigate the efficacy and safety of glimepiride as initial mono-therapy in type 2 diabetes patients (T2DM). Materials and Methods. This is a multi-center, open-label prospective observational study. 245 treatment-naive T2DM patients, who had not achieved glycemic goals on lifestyle therapy during first 12 weeks after the diagnosis, were enrolled in this study. Anti-diabetes treatment was initiated with glimepiride and continued during the 6-month follow-up period. Prescription of the initial dose (1 mg per day) and further dose adjustments were carried out by the attending physician in accordance with the glimepiride data sheet. Dynamics of HbA1c, fasting plasma glucose (FPG), 2 h postprandial blood glucose (2hPPG), weight and waist circumference, as well as the incidence of hypoglycemia were the evaluated parameters. Results. The baseline HbA1c (mean: 7.9?0.5%; female: 7.8?0.4% ; male: 8.0?0.6%) was significantly reduced at week 12 (mean 7.2?0.6%, phttps://www.dia-endojournals.ru/jour/article/view/6276hemoglobin a1cdiabetes mellitusglimepiridehypoglycemic agents |
| spellingShingle | Alexander Sergeevich Ametov Fatima Totrazovna Abaeva Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus Сахарный диабет hemoglobin a1c diabetes mellitus glimepiride hypoglycemic agents |
| title | Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus |
| title_full | Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus |
| title_fullStr | Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus |
| title_full_unstemmed | Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus |
| title_short | Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus |
| title_sort | efficacy and safety of glimepiride as initial treatment in russian patients with type 2 diabetes mellitus |
| topic | hemoglobin a1c diabetes mellitus glimepiride hypoglycemic agents |
| url | https://www.dia-endojournals.ru/jour/article/view/6276 |
| work_keys_str_mv | AT alexandersergeevichametov efficacyandsafetyofglimepirideasinitialtreatmentinrussianpatientswithtype2diabetesmellitus AT fatimatotrazovnaabaeva efficacyandsafetyofglimepirideasinitialtreatmentinrussianpatientswithtype2diabetesmellitus |